Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma

Autor: Désiré Challuau, Benoît Hosten, Michel Perricaudet, Céline Bouquet, Sylvie Marion, Sophie Gil, Robert Farinotti, Mario Di Palma, Laurence Bonhomme-Faivre
Přispěvatelé: Vectorologie et transfert de gènes (VTG / UMR8121), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS)
Rok vydání: 2006
Předmět:
MESH: Combined Modality Therapy
Cancer Research
Administration
Oral
Pharmacology
030226 pharmacology & pharmacy
law.invention
Carcinoma
Lewis Lung
Mice
chemistry.chemical_compound
0302 clinical medicine
law
Recombinant interleukin-2
MESH: Animals
Pharmacology (medical)
Lung
P-glycoprotein
MESH: Carcinoma
Lewis Lung
medicine.diagnostic_test
biology
hemic and immune systems
Combined Modality Therapy
Recombinant Proteins
3. Good health
medicine.anatomical_structure
Oncology
Paclitaxel
030220 oncology & carcinogenesis
MESH: Administration
Oral
Toxicity
Recombinant DNA
Female
MESH: P-Glycoprotein
Injections
Subcutaneous
MESH: Antineoplastic Agents
Phytogenic
Blotting
Western
[SDV.CAN]Life Sciences [q-bio]/Cancer
chemical and pharmacologic phenomena
03 medical and health sciences
Western blot
MESH: Mice
Inbred C57BL
medicine
MESH: Blotting
Western
Animals
MESH: Lung
MESH: Paclitaxel
ATP Binding Cassette Transporter
Subfamily B
Member 1
MESH: Mice
business.industry
MESH: Recombina
MESH: Injections
Subcutaneous
Lewis lung carcinoma
MESH: Interleukin-2
Antineoplastic Agents
Phytogenic
Mice
Inbred C57BL
chemistry
Immunology
biology.protein
Interleukin-2
business
MESH: Female
Zdroj: Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2006, 17 (2), pp.195-9
ISSN: 0959-4973
1473-5741
DOI: 10.1097/00001813-200602000-00011
Popis: International audience; The aim of the present study was to examine modifications of anti-tumor activity and toxicity of paclitaxel (PLX) when given p.o. after recombinant interleukin-2 (rIL-2) to Lewis lung carcinoma-bearing mice. PLX was given orally to mice at the dose of 15 mg/kg on day 8 and 30 mg/kg on day 15, either alone or after 16.5 microg of rIL-2 given i.p. twice a day either 1 or 3 days before. The anti-tumor activity was higher and PLX hematological toxicity not increased if orally administered PLX was given after a 3-day rIL-2 pre-treatment rather than if given alone. Lung metastasis was significantly lower and s.c. tumors were smaller in the PLX+rIL-2 group than in the PLX or rIL-2 or non-treated groups. In addition, a decrease in lung P-glycoprotein expression (investigated by Western blot analysis) was observed 1 h after the last administration of rIL-2 on day 7.
Databáze: OpenAIRE
Externí odkaz: